Bridge Therapeutics, a late development-stage specialty pharmaceutical company, has added Steven Passik PhD to its Scientific Advisory Board, it was reported yesterday.
Dr Passik PhD, Clinical Psychology, is a leader and researcher in pain management and addiction. He has written extensively on the treatment of cancer and AIDS patient's pain management. He has been a principal investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organisations. He has been the recipient of numerous awards for his excellence in clinical research.
Dr Greg Sullivan, chief science officer and founder of Bridge Therapeutics said, 'Dr Passik has a wealth of knowledge on the practical application of pain management in the real world, not just in the clinical setting. I'm excited to see what he will add to Bridge's efforts in developing safer chronic pain treatments.'
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence